FEZF1-AS1

Summary

FEZF1-AS1 (FEZF1 antisense RNA 1, HGNC:41001) is a long non-coding RNA gene on chromosome 7q31.32.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:41001
Approved symbol	FEZF1-AS1
Name	FEZF1 antisense RNA 1
Location	7q31.32
Locus type	RNA, long non-coding
Status	Approved
Ensembl gene	ENSG00000230316
Ensembl biotype	lncRNA
Entrez	154860
RNAcentral	URS00004DA37A — lncRNA, 2653 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 lncRNA

ENST00000424404, ENST00000428449, ENST00000437317, ENST00000653165

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000424404 — 2 exons

Exon	Start	End
ENSE00001698567	122306881	122307488
ENSE00001736757	122308487	122308557

Expression profiles

Bgee: expression breadth ubiquitous, 107 present calls, max score 81.86.

FANTOM5 (CAGE): breadth broad, TPM avg 5.4369 / max 637.6356, expressed in 220 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
80842	1.9250	102
80840	1.2020	76
80835	1.1713	179
80836	0.5047	94
80841	0.1802	48
80839	0.1212	34
80837	0.0955	37
80838	0.0949	36
80845	0.0611	30
80844	0.0586	27

Top tissues by expression

107 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
caudate nucleus	UBERON:0001873	81.86	gold quality
amygdala	UBERON:0001876	81.42	gold quality
temporal lobe	UBERON:0001871	81.08	gold quality
putamen	UBERON:0001874	79.23	gold quality
hypothalamus	UBERON:0001898	77.47	gold quality
sural nerve	UBERON:0015488	77.13	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	76.27	gold quality
nucleus accumbens	UBERON:0001882	76.02	gold quality
adenohypophysis	UBERON:0002196	74.07	gold quality
calcaneal tendon	UBERON:0003701	71.06	gold quality
ventricular zone	UBERON:0003053	68.90	gold quality
cortex of kidney	UBERON:0001225	65.50	gold quality
endometrium	UBERON:0001295	65.13	gold quality
pituitary gland	UBERON:0000007	64.73	gold quality
substantia nigra	UBERON:0002038	63.89	gold quality
brain	UBERON:0000955	62.90	gold quality
ganglionic eminence	UBERON:0004023	62.67	gold quality
skeletal muscle tissue	UBERON:0001134	61.56	silver quality
lower esophagus mucosa	UBERON:0035834	55.65	gold quality
monocyte	CL:0000576	53.82	gold quality
muscle of leg	UBERON:0001383	53.43	gold quality
prefrontal cortex	UBERON:0000451	53.08	gold quality
superior frontal gyrus	UBERON:0002661	52.47	gold quality
gastrocnemius	UBERON:0001388	52.40	gold quality
Ammon’s horn	UBERON:0001954	52.32	gold quality
right lobe of liver	UBERON:0001114	52.21	gold quality
primary visual cortex	UBERON:0002436	52.16	gold quality
hindlimb stylopod muscle	UBERON:0004252	52.16	gold quality
liver	UBERON:0002107	51.82	gold quality
multicellular organism	UBERON:0000468	51.75	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.48

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 24)

• Findings indicate that the dysregulation of FEZF1-AS1 participates in colorectal tumorigenesis and progression, which might be achieved, at least in part, through FEZF1 induction. (PMID:26848625)
• Results provide evidence that FEZF1-AS1 is overexpressed in gastric cancer tissues; its overexpression may predict poor prognosis. FEZF1-AS1 promoted gastric cancer cell proliferation and tumorigenesis by affecting cell cycle progression partly through suppressing P21 expression. (PMID:28209170)
• These results suggest that lncRNA FEZF-AS1 relate to the progression of lung cancer patients (PMID:29709443)
• our study validate the important role of FEZF1-AS1/miR-30a/Nanog in breast cancer stemness and tumorigenesis, providing a novel insight and treatment strategy for breast cancer. (PMID:29797562)
• FEZF1-AS1 promoted multiple myeloma cells proliferation through regulating miR-610/Akt3 axis. (PMID:29864963)
• these data provide mechanistic insights into the regulation of FEZF1-AS1 on both STAT3 signaling and glycolysis by binding PKM2 and increasing its stability. (PMID:29914894)
• FEZF1-AS1 acts as an oncogenic lncRNA in human hepatocellular carcinoma by promoting JAK2/STAT3 signaling-mediated epithelial mesenchymal transformation. (PMID:29957463)
• the results of the present study demonstrated that FEZF1-AS1 promoted the proliferation, migration and invasion of HCC cells by regulating miR-4443 expression levels. The present results highlight the importance of the FEZF1-AS1/miR-4443 axis during HCC development and progression. (PMID:30365146)
• Loss-of-function study indicated silencing FEZF1-AS1 expression inhibited retinoblastoma cell proliferation, invasion and migration. In conclusion, FEZF1-AS1 functions as an oncogenic lncRNA in retinoblastoma. (PMID:31076545)
• FEZF1-AS1: a novel vital oncogenic lncRNA in multiple human malignancies. (PMID:31175144)
• Study shows that increased lncRNA FEZF1- AS1 expression is significantly associated with unfavorable clinical outcomes in patients with solid tumors. As a vital node in the gene expression pathway, lncRNA FEZF1-AS1 is regulated by upstream molecules and regulating the occurrence and progression of cancer cells in multiple ways. [meta-analysis] (PMID:31192939)
• role of FEZF1-AS1 in carcinogenesis and progression suggests that it may be a potential diagnostic biomarker or a novel therapeutic target for cancers (PMID:31276636)
• Highly expressed long non-coding RNA FEZF1-AS1 promotes cells proliferation and metastasis through Notch signaling in prostate cancer. (PMID:31298365)
• LncRNA FEZF1-AS1 promotes non-small lung cancer cell migration and invasion through the up-regulation of NOTCH1 by serving as a sponge of miR-34a. (PMID:32349744)
• lncRNA FEZF1AS1 promotes migration, invasion and epithelialmesenchymal transition of retinoblastoma cells by targeting miR12363p. (PMID:32901841)
• Upregulated long noncoding RNAs LINC02163 and FEZF1-AS1 exert oncogenic roles in colorectal cancer. (PMID:32932277)
• Long noncoding RNA FEZF1AS1 facilitates nonsmall cell lung cancer progression via the ITGA11/miR516b5p axis. (PMID:33174014)
• LncRNA FEZF1-AS1 accelerates the migration and invasion of laryngeal squamous cell carcinoma cells through miR-4497 targeting GBX2. (PMID:33550476)
• Long non-coding RNA FEZF1-AS1 promotes the proliferation and metastasis of hepatocellular carcinoma via targeting miR-107/Wnt/beta-catenin axis. (PMID:34023817)
• Up-Regulated LncRNA FEZF1-AS1 Promotes the Progression of Cervical Carcinoma Cells via MiR-367-3p/SLC12A5 Signal Axis. (PMID:34362591)
• LncRNA FEZF1-AS1 aggravates cell proliferation and migration in glioblastoma. (PMID:34530115)
• Long non-coding RNA FEZF1-AS1 promotes rectal cancer progression by competitively binding miR-632 with FAM83A. (PMID:35607960)
• Up-regulation of BOK-AS1, FAM215A and FEZF1-AS1 lncRNAs and their potency as moderate diagnostic biomarkers in gastric cancer. (PMID:37364417)
• [Overexpression of lncRNA FEZF1-AS1 promotes progression of non-small cell lung cancer via the miR-130a-5p/CCND1 axis]. (PMID:38862441)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.